FDAnews
www.fdanews.com/articles/73900-osi-pharmaceuticals-grants-license-to-merck

OSI PHARMACEUTICALS GRANTS LICENSE TO MERCK

June 30, 2005

OSI Pharmaceuticals has announced that its diabetes and obesity business unit (OSI) Prosidion, has granted Merck a worldwide, non-exclusive license under U.S. Patent No. 6,890,898 and foreign equivalents thereof which claim combination therapy comprising administration of a DPIV inhibitor and another therapeutic agent for the treatment of Type 2 diabetes and related indications. OSI will receive upfront, milestone and royalty payments. Additional financial terms were not disclosed.

BioSpace

(http://home.businesswire.com/portal/site/biospace/index.jsp?epi-content=GENERIC&newsId=20050630005022&ndmHsc=v2*A1119524400000*B1120165185000*DgroupByDate*J2*N1000122&newsLang=en&beanID=1229976837&viewID=news_view)